Inhibitor mutations by Illumina MiSeq. Retrovirology 11, 122 (2014). 14. Ram, D. et al. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. J. Virol. Methods 212, 12?6 (2015). 15. Archer, J. et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS ONE
Predicted that for the antibody to be effective in neutralizing HIV-1, the time it takes to disable an epitope must be shorter than the time the epitope remains in the long-lived conformation induced by antibody binding. For 4E10 and 2F5, whose dissociation rate constants for the breakup of the long-lived complex k{d 10{3 s21 (Table 1 and [4,17]), the time to disable an epitope must be about five
Inhibitor mutations by Illumina MiSeq. Retrovirology 11, 122 (2014). 14. Ram, D. et al. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. J. Virol. Methods 212, 12?6 (2015). 15. Archer, J. et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS ONE
Inhibitor mutations by Illumina MiSeq. Retrovirology 11, 122 (2014). 14. Ram, D. et al. Evaluation of GS Junior and MiSeq next-generation sequencing technologies as an alternative to Trugene population sequencing in the clinical HIV laboratory. J. Virol. Methods 212, 12?6 (2015). 15. Archer, J. et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS ONE
Anti-HIV therapeutic levels in the CNS.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptDISCUSSIONEffective CNS delivery of many drugs, especially hydrophilic and negatively charged molecules, still remains an unsolved dilemma. Progress of nanotechnology and development of novel particulate drug delivery systems resulted in the extensive search for drug nanoformulations th
Ion sequencing platforms for determining HIV-1 coreceptor useSt hanie Raymond1,2,3, Florence Nicot3, Nicolas Jeanne3, Olivier Delfour3, Romain Carcenac3, Caroline Lefebvre3, Michelle Cazabat1,3, Karine Saun?,2,3, Pierre Delobel1,2,4 Jacques Izopet1,2,The coreceptor used by HIV-1 must be determined before a CCR5 antagonist, part of the arsenal of antiretroviral drugs, is prescribed because viruse
Ion sequencing platforms for determining HIV-1 coreceptor useSt hanie Raymond1,2,3, Florence Nicot3, Nicolas Jeanne3, Olivier Delfour3, Romain Carcenac3, Caroline Lefebvre3, Michelle Cazabat1,3, Karine Saun?,2,3, Pierre Delobel1,2,4 Jacques Izopet1,2,The coreceptor used by HIV-1 must be determined before a CCR5 antagonist, part of the arsenal of antiretroviral drugs, is prescribed because viruse
Ion sequencing platforms for determining HIV-1 coreceptor useSt hanie Raymond1,2,3, Florence Nicot3, Nicolas Jeanne3, Olivier Delfour3, Romain Carcenac3, Caroline Lefebvre3, Michelle Cazabat1,3, Karine Saun?,2,3, Pierre Delobel1,2,4 Jacques Izopet1,2,The coreceptor used by HIV-1 must be determined before a CCR5 antagonist, part of the arsenal of antiretroviral drugs, is prescribed because viruse